Orforglipron
Foundayo
Sources
fda, as of 2026-04-01Stale
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220934Orig1s000ltr.pdf
Eli Lilly and Company. This NDA provides for the use of Foundayo (orforglipron) tablets in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. It is approved, effective on the date of this letter.
NDA 220934 approval letter, signature date 04/01/2026
registry, as of 2026-08-14Stale
https://clinicaltrials.gov/study/NCT05869903
Protocol section, NCT05869903 ATTAIN-1, last update posted 2026-08-14
registry, as of 2026-04-17Stale
https://clinicaltrials.gov/study/NCT05803421
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 2749. Conditions Type 2 Diabetes; Obesity; Overweight or Obesity; Overweight; Cardiovascular Diseases; Chronic Kidney Disease. The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits
ClinicalTrials.gov NCT05803421 protocol and results modules
registry, as of 2026-11-05
https://clinicaltrials.gov/study/NCT07794579
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 2001. Conditions Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal. This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diabetes, hypertension, and dyslipidemia, and progression to class 1 obesity.
ClinicalTrials.gov NCT07794579 protocol and results modules
registry, as of 2026-09-04Stale
https://clinicaltrials.gov/study/NCT05872620
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1613. Conditions Obesity; Overweight; Type 2 Diabetes. This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits. Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline Placebo 24.4 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 6 mg Orforglipron QD 49.8 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 12 mg Orfor
ClinicalTrials.gov NCT05872620 protocol and results modules
registry, as of 2026-07-31Stale
https://clinicaltrials.gov/study/NCT06993792
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1400. Conditions Obesity; Overweight; Type 2 Diabetes. The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they wi
ClinicalTrials.gov NCT06993792 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT07202884
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 1000. Conditions Urinary Incontinence,Stress. The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during m
ClinicalTrials.gov NCT07202884 protocol and results modules
registry, as of 2026-05-29Stale
https://clinicaltrials.gov/study/NCT06948422
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening). Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 974. Conditions Hypertension. The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overwei
ClinicalTrials.gov NCT06948422 protocol and results modules
registry, as of 2026-10-08Stale
https://clinicaltrials.gov/study/NCT07153471
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Osteoarthritis. The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo
ClinicalTrials.gov NCT07153471 protocol and results modules
registry, as of 2026-07-29Stale
https://clinicaltrials.gov/study/NCT06972459
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 800. Conditions Obesity; Overweight. The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study
ClinicalTrials.gov NCT06972459 protocol and results modules
registry, as of 2026-09-14Stale
https://clinicaltrials.gov/study/NCT06649045
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 712. Conditions OSA; Overweight or Obesity. Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have modera
ClinicalTrials.gov NCT06649045 protocol and results modules
registry, as of 2026-04-20Stale
https://clinicaltrials.gov/study/NCT06972472
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 600. Conditions Obesity; Overweight; Type 2 Diabetes. The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the s
ClinicalTrials.gov NCT06972472 protocol and results modules
registry, as of 2026-05-29Stale
https://clinicaltrials.gov/study/NCT06952530
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 487. Conditions Hypertension. GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
ClinicalTrials.gov NCT06952530 protocol and results modules
registry, as of 2026-05-29Stale
https://clinicaltrials.gov/study/NCT06948435
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 487. Conditions Hypertension; Overweight or Obesity. GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.
ClinicalTrials.gov NCT06948435 protocol and results modules
registry, as of 2026-06-04Stale
https://clinicaltrials.gov/study/NCT06584916
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN). Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 376. Conditions Obesity; Overweight. The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT0
ClinicalTrials.gov NCT06584916 protocol and results modules
registry, as of 2026-07-20Stale
https://clinicaltrials.gov/study/NCT05931380
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 238. Conditions Obesity. The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems. Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline Placebo QD 15.0 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 6 mg Orforglipron QD 45.9 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline 12 mg Orforglipron QD 61.4 Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From B
ClinicalTrials.gov NCT05931380 protocol and results modules
registry, as of 2026-10-13Stale
https://clinicaltrials.gov/study/NCT07790861
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 192. Conditions Obesity; Overweight. The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
ClinicalTrials.gov NCT07790861 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT06672939
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities. Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 150. Conditions Obesity; Overweight. The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. P
ClinicalTrials.gov NCT06672939 protocol and results modules
registry, as of 2026-11-04
https://clinicaltrials.gov/study/NCT06672549
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040). Overall status RECRUITING. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 125. Conditions Obesity; Overweight. The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
ClinicalTrials.gov NCT06672549 protocol and results modules
registry, as of 2026-07-27Stale
https://clinicaltrials.gov/study/NCT07729332
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation. Overall status NOT_YET_RECRUITING. Phases PHASE4. Lead sponsor Massachusetts General Hospital. Enrollment 60. Conditions Obesity. This study will compare the effect of orforglipron and phentermine on weight maintenance.
ClinicalTrials.gov NCT07729332 protocol and results modules
registry, as of 2026-07-17Stale
https://clinicaltrials.gov/study/NCT06440980
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 533. Conditions Healthy; Obese; Overweight; Obesity. The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effe
ClinicalTrials.gov NCT06440980 protocol and results modules
registry, as of 2026-02-25Stale
https://clinicaltrials.gov/study/NCT06824051
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 120. Conditions Obesity; Overweight. The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.
ClinicalTrials.gov NCT06824051 protocol and results modules
registry, as of 2026-09-11Stale
https://clinicaltrials.gov/study/NCT07793019
IBI3042 Study in Healthy Participants and Overweight or Obese Participants. Overall status RECRUITING. Phases PHASE1. Lead sponsor Innovent Biologics (Suzhou) Co. Ltd.. Enrollment 104. Conditions Overweight; Healthy Participants; Obesity. This is a Phase 1 study of IBI3042, an investigational oral medicine being developed as a potential treatment for overweight and obesity. The study has two parts. Part A will evaluate single doses of IBI3042 in healthy adults. Part B will evaluate repeated doses for 13 weeks in a
ClinicalTrials.gov NCT07793019 protocol and results modules
registry, as of 2026-05-22Stale
https://clinicaltrials.gov/study/NCT06186622
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 50. Conditions Healthy; Obese; Overweight. The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body
ClinicalTrials.gov NCT06186622 protocol and results modules
publication, as of 2025-11-05Stale
https://pubmed.ncbi.nlm.nih.gov/40960239/
Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of
PMID 40960239